SEC Form 4 · accession 0000899243-19-004728
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Erland Johnson
Officer — See Remarks
Period of report
Feb 19, 2019
Accepted (ET)
Feb 25, 2019 · 5:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 19, 2019 | P | 1,000 | $10.00 | A | 3,245 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Mr. Johnson purchased shares of common stock from the underwriters in a public offering pursuant to the registrant's Registration Statement on Form S-1 (File No. 333-229665, completed on February 19, 2019). The shares of common stock were purchased at the public offering price.
Remarks
Senior Vice President Clinical Development, Quality Assurance, and Medical Affairs